Global Tuberculosis Therapeutics Market Report 2025

Tuberculosis Therapeutics Global Market Report 2025 – By Type (Active Tuberculosis (TB), Latent Tuberculosis (TB)), By Product Type (Isoniazid, Rifampin, Pyrazinamide, Hydrazine derivatives, Miscellaneous anti-tubercular drugs, Ethambutol), By Route of Administration (Oral, Parenteral, Other route of administration), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By End-User (Hospitals, Clinics, Ambulatory Surgical Centers, Other End-Users) – Market Size, Trends, And Global Forecast 2025-2034

Tuberculosis Therapeutics Global Market Report 2025

Report Price : $4490.00 | Pages : | Published : January 2025 | Delivery Time: 2-3 business days | Format : pdf

Need assistance or more information before the purchase?

Enquire Before Buying
Tuberculosis Therapeutics Global Market Report 2025

Proud Members Of

checkslacipN checkaoirsN checkscipN

Tuberculosis Therapeutics Market Definition

Tuberculosis therapeutics refers to the pharmaceutical treatments designed to prevent and cure tuberculosis (TB), a bacterial infection caused by Mycobacterium tuberculosis. The purpose of these therapeutics is to eradicate the bacteria, reduce transmission, and improve patient outcomes, particularly for those with drug-resistant strains.

The main types of tuberculosis therapeutics are active tuberculosis (tb) and latent tuberculosis (tb). Active tuberculosis (TB) is a contagious bacterial infection caused by Mycobacterium tuberculosis that primarily affects the lungs, causing symptoms like persistent cough, fever, and weight loss. There are different product types available, like isoniazid, rifampin, pyrazinamide, hydrazine derivatives, miscellaneous anti-tubercular drugs, and ethambutol. Its routes of administration types are oral, parenteral, and others, and they are distributed through various channels such as hospital pharmacy, retail pharmacy, and online pharmacy and are used by several end users, including hospitals, clinics, ambulatory surgical centers, and others.

Tuberculosis Therapeutics Market Segmentation

The tuberculosis therapeutics market covered in this report is segmented –

1) By Type: Active Tuberculosis (TB), Latent Tuberculosis (TB)

2) By Product Type: Isoniazid, Rifampin, Pyrazinamide, Hydrazine derivatives, Miscellaneous anti-tubercular drugs, Ethambutol

3) By Route of Administration: Oral, Parenteral, Other route of administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Other End-Users

Subsegments:

1) By Active Tuberculosis (TB): First-Line Drugs (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol), Second-Line Drugs (Fluoroquinolones, Aminoglycosides), Combination Therapies, Drug-Resistant TB Treatments (MDR-TB, XDR-TB)

2) By Latent Tuberculosis (TB): Isoniazid Prophylaxis, Rifampicin-Based Regimens, Rifapentine-Based Regimens, Combination Prophylactic Therapies

Tuberculosis Therapeutics Market Size and growth rate 2025 to 2029: Graph

Tuberculosis Therapeutics Market Size 2025 And Growth Rate

The tuberculosis therapeutics market size has grown strongly in recent years. It will grow from $1.88 billion in 2024 to $2.01 billion in 2025 at a compound annual growth rate (CAGR) of 6.58%. The growth in the historic period can be attributed to the rising incidence of tuberculosis, growing adoption of tuberculosis therapeutics, increased awareness about tuberculosis (TB), rising incidence of XDR-TB, and increasing incidence of drug-resistant tuberculosis.

Tuberculosis Therapeutics Market Growth Forecast

The tuberculosis therapeutics market size is expected to see strong growth in the next few years. It will grow to $2.57 billion in 2029 at a compound annual growth rate (CAGR) of 6.32%. The growth in the forecast period can be attributed to increasing investments in healthcare infrastructure, growing awareness and education, a rise in investments for research and development, a rise in product approvals of various anti-TB agents, increased research funding, and a growing number of geriatric populations. Major trends in the forecast period include advancements in drug development, personalized medicine, combination therapies, digital health solutions, AI, and machine learning in drug discovery.

Tuberculosis Therapeutics Market Driver: Impact Of Rising TB-HIV Co-Infection Rates On The Growth Of The Market

Rising co-infection rates (TB-HIV) are expected to propel the growth of the tuberculosis therapeutics market going forward. Co-infection rates (TB-HIV) refer to the percentage of individuals who are simultaneously infected with both tuberculosis (TB) and the human immunodeficiency virus (HIV). Rising co-infection rates (TB-HIV) occur due to the weakened immune system caused by HIV, making individuals more susceptible to tuberculosis, and the global overlap of both epidemics in high-risk populations. Tuberculosis therapeutics help rising co-infection rates (TB-HIV) by providing targeted treatments that address both TB infection and HIV-related immune suppression, improving overall patient outcomes and reducing the burden of both diseases. For instance, in October 2023, according to the gov.uk, a UK-based public sector, in 2022, England reported 3,805 new HIV diagnoses, marking a 22% increase from the 3,118 cases recorded in 2021. Therefore, rising co-infection rates (TB-HIV) are driving the growth of the tuberculosis therapeutics market.

Global Tuberculosis Therapeutics Market Major Players

Major companies operating in the tuberculosis therapeutics market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Macleods Pharmaceuticals Ltd., Cipla Limited, Hikma Pharmaceuticals plc, Lupin Limited, Alkem Laboratories Limited, Emcure Pharmaceuticals Limited, Otsuka Pharmaceutical Co. Ltd., Sequella Inc.

Global Tuberculosis Therapeutics Market Trend: Advancements In Tuberculosis Therapeutics For Drug Resistance

Major companies operating in the tuberculosis therapeutics market are focusing on developing innovative solutions, such as combination therapy, to improve treatment efficacy, reduce the duration of therapy, and combat drug-resistant strains of tuberculosis. Combination therapy refers to the use of two or more medications from different classes to treat a disease, aiming to increase treatment efficacy, reduce resistance, and improve patient outcomes. For instance, in July 2024, Johnson & Johnson, a US-based pharmaceutical company, achieved a significant milestone in tuberculosis treatment with the approval of SIRTURO (bedaquiline) by both the U.S. FDA and the European Commission. This innovative drug is the first in over four decades specifically designed to target multidrug-resistant tuberculosis (MDR-TB). Its unique mechanism of action, inhibiting the ATP synthase enzyme essential for TB bacteria's energy production, thereby offering a targeted and effective therapeutic approach. Its inclusion in combination therapies enhances the overall efficacy of MDR-TB regimens, reducing treatment duration and improving patient compliance.

Tuberculosis Therapeutics Market Merger And Acquisition: BioVersys And GSK Form Strategic Partnership To Advance Alpibectir Development For Tuberculosis Treatment

In May 2024, BioVersys AG, a Switzerland-based biotechnology company, partnered with GSK plc. Through their strategic collaboration, GSK and BioVersys intend to expedite the clinical advancement of alpibectir (BVL-GSK098) for the treatment of tuberculosis (TB). GSK plc is a UK-based pharmaceutical company that focuses on the development and manufacture of innovative medicines, including tuberculosis (TB) therapeutics.

Regional Outlook For The Global Tuberculosis Therapeutics Market

North America was the largest region in the tuberculosis therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tuberculosis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the tuberculosis therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Tuberculosis Therapeutics Market?

The tuberculosis therapeutics market consists of sales of combination therapies, vaccines, supportive therapies, biologics, and newer drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Tuberculosis Therapeutics Industry?

The tuberculosis therapeutics market research report is one of a series of new reports from The Business Research Company that provides tuberculosis therapeutics market statistics, including the tuberculosis therapeutics industry global market size, regional shares, competitors with the tuberculosis therapeutics market share, detailed tuberculosis therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the tuberculosis therapeutics industry. This tuberculosis therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Tuberculosis Therapeutics Market Report Forecast Analysis
Report AttributeDetails
Market Size Value In 2025 2.01 billion
Revenue Forecast In 2034 $2.57 billion
Growth Rate CAGR of 6.32% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered The tuberculosis therapeutics market covered in this report is segmented –
1) By Type: Active Tuberculosis (TB), Latent Tuberculosis (TB)
2) By Product Type: Isoniazid, Rifampin, Pyrazinamide, Hydrazine derivatives, Miscellaneous anti-tubercular drugs, Ethambutol
3) By Route of Administration: Oral, Parenteral, Other route of administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Other End-Users Subsegments:
1) By Active Tuberculosis (TB): First-Line Drugs (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol), Second-Line Drugs (Fluoroquinolones, Aminoglycosides), Combination Therapies, Drug-Resistant TB Treatments (MDR-TB, XDR-TB)
2) By Latent Tuberculosis (TB): Isoniazid Prophylaxis, Rifampicin-Based Regimens, Rifapentine-Based Regimens, Combination Prophylactic Therapies
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Macleods Pharmaceuticals Ltd., Cipla Limited, Hikma Pharmaceuticals plc, Lupin Limited, Alkem Laboratories Limited, Emcure Pharmaceuticals Limited, Otsuka Pharmaceutical Co. Ltd., Sequella Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Tuberculosis Therapeutics Market Characteristics

    3. Tuberculosis Therapeutics Market Trends And Strategies

    4. Tuberculosis Therapeutics Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

    5. Global Tuberculosis Therapeutics Growth Analysis And Strategic Analysis Framework

    5.1. Global Tuberculosis Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

    5.2. Analysis Of End Use Industries

    5.3. Global Tuberculosis Therapeutics Market Growth Rate Analysis

    5.4. Global Tuberculosis Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

    5.5. Global Tuberculosis Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

    5.6. Global Tuberculosis Therapeutics Total Addressable Market (TAM)

    6. Tuberculosis Therapeutics Market Segmentation

    6.1. Global Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Active Tuberculosis (TB)

    Latent Tuberculosis (TB)

    6.2. Global Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Isoniazid

    Rifampin

    Pyrazinamide

    Hydrazine Derivatives

    Miscellaneous Anti-Tubercular Drugs

    Ethambutol

    6.3. Global Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Oral

    Parenteral

    Other Route of Administration

    6.4. Global Tuberculosis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Hospital Pharmacy

    Retail Pharmacy

    Online Pharmacy

    Other Distribution Channels

    6.5. Global Tuberculosis Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Hospitals

    Clinics

    Ambulatory Surgical Centers

    Other End-Users

    6.6. Global Tuberculosis Therapeutics Market, Sub-Segmentation Of Active Tuberculosis (TB), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    First-Line Drugs (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol)

    Second-Line Drugs (Fluoroquinolones, Aminoglycosides)

    Combination Therapies

    Drug-Resistant TB Treatments (MDR-TB, XDR-TB)

    6.7. Global Tuberculosis Therapeutics Market, Sub-Segmentation Of Latent Tuberculosis (TB), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Isoniazid Prophylaxis

    Rifampicin-Based Regimens

    Rifapentine-Based Regimens

    Combination Prophylactic Therapies

    7. Tuberculosis Therapeutics Market Regional And Country Analysis

    7.1. Global Tuberculosis Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    7.2. Global Tuberculosis Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8. Asia-Pacific Tuberculosis Therapeutics Market

    8.1. Asia-Pacific Tuberculosis Therapeutics Market Overview

    Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.3. Asia-Pacific Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.4. Asia-Pacific Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    9. China Tuberculosis Therapeutics Market

    9.1. China Tuberculosis Therapeutics Market Overview

    9.2. China Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.3. China Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.4. China Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    10. India Tuberculosis Therapeutics Market

    10.1. India Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.2. India Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.3. India Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11. Japan Tuberculosis Therapeutics Market

    11.1. Japan Tuberculosis Therapeutics Market Overview

    11.2. Japan Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.3. Japan Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.4. Japan Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12. Australia Tuberculosis Therapeutics Market

    12.1. Australia Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.2. Australia Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.3. Australia Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13. Indonesia Tuberculosis Therapeutics Market

    13.1. Indonesia Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.2. Indonesia Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.3. Indonesia Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14. South Korea Tuberculosis Therapeutics Market

    14.1. South Korea Tuberculosis Therapeutics Market Overview

    14.2. South Korea Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.3. South Korea Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.4. South Korea Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15. Western Europe Tuberculosis Therapeutics Market

    15.1. Western Europe Tuberculosis Therapeutics Market Overview

    15.2. Western Europe Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.3. Western Europe Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.4. Western Europe Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16. UK Tuberculosis Therapeutics Market

    16.1. UK Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.2. UK Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.3. UK Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17. Germany Tuberculosis Therapeutics Market

    17.1. Germany Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.2. Germany Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.3. Germany Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18. France Tuberculosis Therapeutics Market

    18.1. France Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.2. France Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.3. France Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19. Italy Tuberculosis Therapeutics Market

    19.1. Italy Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.2. Italy Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.3. Italy Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20. Spain Tuberculosis Therapeutics Market

    20.1. Spain Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.2. Spain Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.3. Spain Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21. Eastern Europe Tuberculosis Therapeutics Market

    21.1. Eastern Europe Tuberculosis Therapeutics Market Overview

    21.2. Eastern Europe Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.3. Eastern Europe Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.4. Eastern Europe Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22. Russia Tuberculosis Therapeutics Market

    22.1. Russia Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.2. Russia Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.3. Russia Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23. North America Tuberculosis Therapeutics Market

    23.1. North America Tuberculosis Therapeutics Market Overview

    23.2. North America Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.3. North America Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.4. North America Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24. USA Tuberculosis Therapeutics Market

    24.1. USA Tuberculosis Therapeutics Market Overview

    24.2. USA Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.3. USA Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.4. USA Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25. Canada Tuberculosis Therapeutics Market

    25.1. Canada Tuberculosis Therapeutics Market Overview

    25.2. Canada Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.3. Canada Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.4. Canada Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26. South America Tuberculosis Therapeutics Market

    26.1. South America Tuberculosis Therapeutics Market Overview

    26.2. South America Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.3. South America Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.4. South America Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27. Brazil Tuberculosis Therapeutics Market

    27.1. Brazil Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.2. Brazil Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.3. Brazil Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28. Middle East Tuberculosis Therapeutics Market

    28.1. Middle East Tuberculosis Therapeutics Market Overview

    28.2. Middle East Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.3. Middle East Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.4. Middle East Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29. Africa Tuberculosis Therapeutics Market

    29.1. Africa Tuberculosis Therapeutics Market Overview

    29.2. Africa Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.3. Africa Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.4. Africa Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    30. Tuberculosis Therapeutics Market Competitive Landscape And Company Profiles

    30.1. Tuberculosis Therapeutics Market Competitive Landscape

    30.2. Tuberculosis Therapeutics Market Company Profiles

    30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

    30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis

    30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis

    30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

    30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

    31. Tuberculosis Therapeutics Market Other Major And Innovative Companies

    31.1. Bayer AG

    31.2. Sanofi S.A.

    31.3. Novartis AG

    31.4. GlaxoSmithKline plc

    31.5. Viatris Inc.

    31.6. Teva Pharmaceutical Industries Ltd.

    31.7. Astellas Pharma Inc.

    31.8. Macleods Pharmaceuticals Ltd.

    31.9. Cipla Limited

    31.10. Hikma Pharmaceuticals plc

    31.11. Lupin Limited

    31.12. Alkem Laboratories Limited

    31.13. Emcure Pharmaceuticals Limited

    31.14. Otsuka Pharmaceutical Co. Ltd.

    31.15. Sequella Inc.

    32. Global Tuberculosis Therapeutics Market Competitive Benchmarking And Dashboard

    33. Key Mergers And Acquisitions In The Tuberculosis Therapeutics Market

    34. Recent Developments In The Tuberculosis Therapeutics Market

    35. Tuberculosis Therapeutics Market High Potential Countries, Segments and Strategies

    35.1 Tuberculosis Therapeutics Market In 2029 - Countries Offering Most New Opportunities

    35.2 Tuberculosis Therapeutics Market In 2029 - Segments Offering Most New Opportunities

    35.3 Tuberculosis Therapeutics Market In 2029 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Tuberculosis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Tuberculosis Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Tuberculosis Therapeutics Market, Sub-Segmentation Of Active Tuberculosis (TB), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Tuberculosis Therapeutics Market, Sub-Segmentation Of Latent Tuberculosis (TB), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Tuberculosis Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Tuberculosis Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Asia-Pacific, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Asia-Pacific, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Asia-Pacific, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: China, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: China, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: China, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: India, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: India, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: India, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: Japan, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Japan, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Japan, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Australia, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Australia, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Australia, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Indonesia, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Indonesia, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Indonesia, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: South Korea, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: South Korea, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: South Korea, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: Western Europe, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Western Europe, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Western Europe, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: UK, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: UK, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: UK, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: Germany, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Germany, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Germany, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: France, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: France, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: France, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: Italy, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Italy, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Italy, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Spain, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Spain, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Spain, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Eastern Europe, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Eastern Europe, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Eastern Europe, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Russia, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Russia, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Russia, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: North America, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: North America, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: North America, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: USA, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: USA, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: USA, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: Canada, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: Canada, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: Canada, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: South America, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: South America, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: South America, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: Brazil, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Brazil, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Brazil, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Middle East, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Middle East, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Middle East, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Africa, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Africa, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Africa, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Pfizer Inc. Financial Performance
  • Table 79: Johnson & Johnson Financial Performance
  • Table 80: Roche Holding AG Financial Performance
  • Table 81: Merck & Co. Inc. Financial Performance
  • Table 82: AbbVie Inc. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Tuberculosis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Tuberculosis Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Tuberculosis Therapeutics Market, Sub-Segmentation Of Active Tuberculosis (TB), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Tuberculosis Therapeutics Market, Sub-Segmentation Of Latent Tuberculosis (TB), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Tuberculosis Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Tuberculosis Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Asia-Pacific, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Asia-Pacific, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Asia-Pacific, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: China, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: China, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: China, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: India, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: India, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: India, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: Japan, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Japan, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Japan, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Australia, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Australia, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Australia, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Indonesia, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Indonesia, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Indonesia, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: South Korea, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: South Korea, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: South Korea, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: Western Europe, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Western Europe, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Western Europe, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: UK, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: UK, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: UK, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: Germany, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Germany, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Germany, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: France, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: France, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: France, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: Italy, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Italy, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Italy, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Spain, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Spain, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Spain, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Eastern Europe, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Eastern Europe, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Eastern Europe, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Russia, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Russia, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Russia, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: North America, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: North America, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: North America, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: USA, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: USA, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: USA, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: Canada, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: Canada, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: Canada, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: South America, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: South America, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: South America, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: Brazil, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Brazil, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Brazil, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Middle East, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Middle East, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Middle East, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Africa, Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Africa, Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Africa, Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Pfizer Inc. Financial Performance
  • Figure 79: Johnson & Johnson Financial Performance
  • Figure 80: Roche Holding AG Financial Performance
  • Figure 81: Merck & Co. Inc. Financial Performance
  • Figure 82: AbbVie Inc. Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report

Frequently Asked Questions

What is the definition of the Tuberculosis Therapeutics market?

Tuberculosis therapeutics refers to the pharmaceutical treatments designed to prevent and cure tuberculosis (TB), a bacterial infection caused by Mycobacterium tuberculosis. The purpose of these therapeutics is to eradicate the bacteria, reduce transmission, and improve patient outcomes, particularly for those with drug-resistant strains. For further insights on the Tuberculosis Therapeutics market, request a sample here

How will the Tuberculosis Therapeutics market drivers and restraints affect the market dynamics? What forces will shape the Tuberculosis Therapeutics industry going forward?

The Tuberculosis Therapeutics market major growth driver - Impact Of Rising TB-HIV Co-Infection Rates On The Growth Of The Market. For further insights on the Tuberculosis Therapeutics market, request a sample here

What is the forecast market size or the forecast market value of the Tuberculosis Therapeutics market?

The Tuberculosis Therapeutics market size has grown strongly in recent years. The tuberculosis therapeutics market size has grown strongly in recent years. It will grow from $1.88 billion in 2024 to $2.01 billion in 2025 at a compound annual growth rate (CAGR) of 6.58%. The growth in the historic period can be attributed to the rising incidence of tuberculosis, growing adoption of tuberculosis therapeutics, increased awareness about tuberculosis (TB), rising incidence of XDR-TB, and increasing incidence of drug-resistant tuberculosis. The tuberculosis therapeutics market size is expected to see strong growth in the next few years. It will grow to $2.57 billion in 2029 at a compound annual growth rate (CAGR) of 6.32%. The growth in the forecast period can be attributed to increasing investments in healthcare infrastructure, growing awareness and education, a rise in investments for research and development, a rise in product approvals of various anti-TB agents, increased research funding, and a growing number of geriatric populations. Major trends in the forecast period include advancements in drug development, personalized medicine, combination therapies, digital health solutions, AI, and machine learning in drug discovery. For further insights on the Tuberculosis Therapeutics market, request a sample here

How is the Tuberculosis Therapeutics market segmented?

The tuberculosis therapeutics market covered in this report is segmented –
1) By Type: Active Tuberculosis (TB), Latent Tuberculosis (TB)
2) By Product Type: Isoniazid, Rifampin, Pyrazinamide, Hydrazine derivatives, Miscellaneous anti-tubercular drugs, Ethambutol
3) By Route of Administration: Oral, Parenteral, Other route of administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Other End-Users Subsegments:
1) By Active Tuberculosis (TB): First-Line Drugs (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol), Second-Line Drugs (Fluoroquinolones, Aminoglycosides), Combination Therapies, Drug-Resistant TB Treatments (MDR-TB, XDR-TB)
2) By Latent Tuberculosis (TB): Isoniazid Prophylaxis, Rifampicin-Based Regimens, Rifapentine-Based Regimens, Combination Prophylactic Therapies For further insights on the Tuberculosis Therapeutics market,
request a sample here

Which region has the largest share of the Tuberculosis Therapeutics market? What are the other regions covered in the report?

North America was the largest region in the tuberculosis therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tuberculosis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on the Tuberculosis Therapeutics market, request a sample here.

Who are the major players in the Tuberculosis Therapeutics market?

Major companies operating in the tuberculosis therapeutics market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Macleods Pharmaceuticals Ltd., Cipla Limited, Hikma Pharmaceuticals plc, Lupin Limited, Alkem Laboratories Limited, Emcure Pharmaceuticals Limited, Otsuka Pharmaceutical Co. Ltd., Sequella Inc. . For further insights on the Tuberculosis Therapeutics market, request a sample here.

What are the key trends in the Tuberculosis Therapeutics market?

Major trends in the Tuberculosis Therapeutics market include Advancements In Tuberculosis Therapeutics For Drug Resistance. For further insights on the Tuberculosis Therapeutics market, request a sample here.

What are the major opportunities in the Tuberculosis Therapeutics market? What are the strategies for the Tuberculosis Therapeutics market?

For detailed insights on the major opportunities and strategies in the Tuberculosis Therapeutics market, request a sample here.

How does the Tuberculosis Therapeutics market relate to the overall economy and other similar markets?

For detailed insights on Tuberculosis Therapeutics's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the Tuberculosis Therapeutics industry?

For detailed insights on the mergers and acquisitions in the Tuberculosis Therapeutics industry, request a sample here.

What are the key dynamics influencing the Tuberculosis Therapeutics market growth? SWOT analysis of the Tuberculosis Therapeutics market.

For detailed insights on the key dynamics influencing the Tuberculosis Therapeutics market growth and SWOT analysis of the Tuberculosis Therapeutics industry, request a sample here.